3(S)-(9H-fluoren-9-ylmethoxycarbonylamino)-N-methoxy-N-methylsuccinamic acid tert-butyl ester | 204973-60-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3(S)-(9H-fluoren-9-ylmethoxycarbonylamino)-N-methoxy-N-methylsuccinamic acid tert-butyl ester
• 英文别名: Fmoc-Asp(tBu)-N(CH3)-OCH3；N-(9-fluorenylmethoxycarbonyl)-N’-methoxy-N’-methyl-L-isoasparagine t-butyl ester；N-(9-fluorenylmethoxycarbonyl)-L-(N'-methyl-N'-methoxy)aspartamide β-(tert-butyl)ester；tert-butyl (3S)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[methoxy(methyl)amino]-4-oxobutanoate
• CAS: 204973-60-4
• 化学式: C₂₅H₃₀N₂O₆
• 分子量: 454.523
• InChiKey: JCYHLFYTHXBULX-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  94.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3(S)-(9H-fluoren-9-ylmethoxycarbonylamino)-N-methoxy-N-methylsuccinamic acid tert-butyl ester 在 lithium aluminium tetrahydride 、 sodium acetate 、 二乙胺 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙腈 为溶剂， 反应 4.5h， 生成 tert-butyl (3S,4E)-3-amino-4-(carbamoylhydrazinylidene)butanoate
  参考文献：
  名称：

  Novel Peptidomimetic Cysteine Protease Inhibitors as Potential Antimalarial Agents

  摘要：

  The synthesis of a new class of peptidomimetics 1a-j, based on a 1,4-benzodiazepine scaffold and on a C-terminal aspartyl aldehyde building block, is described. Compounds 1a-j provided significant inhibitory activity against falcipains 2A and 2B (FP-2A and FP-2B), two cysteine proteases from Plasmodium falciparum.

  DOI：

  10.1021/jm060405f
• 作为产物：
  描述：

  Fmoc-L-天冬氨酸 beta-叔丁酯 、 alkaline earth salt of/the/ methylsulfuric acid 在 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 3(S)-(9H-fluoren-9-ylmethoxycarbonylamino)-N-methoxy-N-methylsuccinamic acid tert-butyl ester
  参考文献：
  名称：

  基于乙烯基砜支架的小分子文库的组合合成。

  摘要：

  [反应：见正文]使用氧化反应和霍纳-沃兹沃思-埃蒙斯反应等基于固相的反应，在滑冰酰胺树脂上制备了一个由30个成员组成的基于乙烯基砜支架的小分子文库。库的设计使得可以轻松地在库中引入三个多样性点，以适应不同半胱氨酸蛋白酶的S（1）'，S（1）和S（2）结合口袋，从而使该策略适用于高通量潜在的半胱氨酸蛋白酶抑制剂的产生。

  DOI：

  10.1021/ol035774+

文献信息

• C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases
  申请人：——

  公开号：US20020042376A1

  公开（公告）日：2002-04-11

  This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新型的oxamyl二肽ICE/ced-3家族抑制剂化合物。该发明还涉及含有这些化合物的药物组合物，以及在治疗患有炎症性、自身免疫和神经退行性疾病的患者中使用这些组合物，用于预防缺血性损伤，并用于保存即将进行移植手术的器官。
• Solid-Phase Synthesis of Peptide Vinyl Sulfones as Potential Inhibitors and Activity-Based Probes of Cysteine Proteases
  作者：Gang Wang、Uttamchandani Mahesh、Grace Y. J. Chen、Shao Q. Yao

  DOI：10.1021/ol0275567

  日期：2003.3.1

  Peptide vinyl sulfones were prepared from 2-chlorotrityl resin-bound phenolic amino vinyl sulfones in high yield and purity. This method enables the convenient synthesis of peptide vinyl sulfones having different amino acids at the P(1) position. It also allows efficient synthesis of vinyl sulfone-containing, activity-based probes of cysteine proteases used in a proteomic experiment.

  由2-氯三苯甲基树脂结合的酚氨基乙烯基乙烯基砜以高收率和纯度制备了肽乙烯基砜。该方法能够方便地合成在P（1）位置具有不同氨基酸的肽乙烯基砜。它还可以有效合成蛋白质组学实验中使用的含乙烯基砜，基于活性的半胱氨酸蛋白酶探针。
• (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases
  申请人：Idun Pharmaceuticals, Inc.

  公开号：US20030232788A1

  公开（公告）日：2003-12-18

  This invention is directed to novel (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

  这项发明涉及新型（取代）酰基二肽酶ICE/ced-3家族抑制剂化合物。该发明还涉及含有这些化合物的药物组合物，以及将这些组合物用于治疗患有炎症、自身免疫和神经退行性疾病的患者，预防缺血性损伤，并保护即将进行移植手术的器官。
• Synthesis of α, β-unsaturated γ-amino esters with unprecedented high (E)-stereoselectivity and their conformational analysis in peptides
  作者：Sachitanand M. Mali、Anupam Bandyopadhyay、Sandip V. Jadhav、Mothukuri Ganesh Kumar、Hosahudya N. Gopi

  DOI：10.1039/c1ob05732d

  日期：——

  Mild, efficient and racemization-free synthesis of N-protected α, β-unsaturated γ-amino esters with unprecedented high E- stereoselectivity is described. This method is found to be compatible with Boc-, Fmoc- and other side chain protecting groups. The crystal conformations of the vinylogous γ-amino esters in monomers and in homo- and mixed dipeptides are studied. Further, the vinylogous homo-dipeptide showed a β-sheet conformation, while mixed α- and α,β-unsaturated γ-hybrid dipeptide adapted an irregular structure in single crystals.

  描述了一种温和、高效且无光学异构化的N保护α, β-不饱和γ-氨基酯的合成方法，该方法具有前所未有的高E型立体选择性。该方法与Boc、Fmoc及其他侧链保护基团相容。研究了单体和同源及混合二肽中乙烯基γ-氨基酯的晶体构象。此外，乙烯基同源二肽显示出β-折叠构象，而混合的α型和α,β-不饱和γ-杂合二肽在单晶中适应了不规则结构。
• Selective Substrates and Activity-Based Probes for Imaging of the Human Constitutive 20S Proteasome in Cells and Blood Samples
  作者：Wioletta Rut、Marcin Poręba、Paulina Kasperkiewicz、Scott J. Snipas、Marcin Drąg

  DOI：10.1021/acs.jmedchem.8b00026

  日期：2018.6.28

  the HyCoSuL approach, we designed and synthesized novel and selective fluorogenic substrates for each of these three constitutive 20S proteasome activities and applied them to assess inhibition of proteasome subunits by MG-132 and a clinically used inhibitor bortezomib. Our results confirm the utility of designed substrates in biochemical assays. Furthermore, selective peptide sequences obtained in this

  蛋白酶体是维持蛋白质稳态的关键酶复合物。蛋白酶体功能紊乱导致包括癌症，自身免疫和神经退行性疾病在内的病理。因此，蛋白酶体构成药物开发的极好的分子靶标。在这里，我们使用HyCoSuL方法为这三个20S组成型蛋白酶体活性中的每一个设计和合成了新颖的选择性荧光底物，并将它们应用于评估MG-132和临床使用的硼替佐米对蛋白酶体亚基的抑制作用。我们的结果证实了设计的底物在生化分析中的实用性。此外，以此方式获得的选择性肽序列用于构建荧光团标记的基于活性的探针，然后用于同时检测HEK-293F细胞和红细胞裂解液中的每个20S组成型蛋白酶体亚基。总体而言，我们描述了一种简单而快速的方法，可用于测量全血样本中20S组成型蛋白酶体的活性，该方法可以早期诊断与异常上调的蛋白酶体活性有关的病理状态。